175 related articles for article (PubMed ID: 15568014)
1. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.
Citri A; Gan J; Mosesson Y; Vereb G; Szollosi J; Yarden Y
EMBO Rep; 2004 Dec; 5(12):1165-70. PubMed ID: 15568014
[TBL] [Abstract][Full Text] [Related]
2. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.
Citri A; Kochupurakkal BS; Yarden Y
Cell Cycle; 2004 Jan; 3(1):51-60. PubMed ID: 14657666
[TBL] [Abstract][Full Text] [Related]
3. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2.
Sidera K; Gaitanou M; Stellas D; Matsas R; Patsavoudi E
J Biol Chem; 2008 Jan; 283(4):2031-41. PubMed ID: 18056992
[TBL] [Abstract][Full Text] [Related]
4. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
5. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
6. Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation.
Huynh TK; Ho CY; Tsai CH; Wang CK; Chen YJ; Bau DT; Tu CY; Li TS; Huang WC
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569723
[TBL] [Abstract][Full Text] [Related]
7. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
8. Extracellular HSP90: conquering the cell surface.
Sidera K; Patsavoudi E
Cell Cycle; 2008 Jun; 7(11):1564-8. PubMed ID: 18469526
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation.
Dietrich M; Malik MS; Nikolaysen F; Skeie M; Stang E
Exp Cell Res; 2018 Oct; 371(1):139-150. PubMed ID: 30098331
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 increases LIM kinase activity by promoting its homo-dimerization.
Li R; Soosairajah J; Harari D; Citri A; Price J; Ng HL; Morton CJ; Parker MW; Yarden Y; Bernard O
FASEB J; 2006 Jun; 20(8):1218-20. PubMed ID: 16641196
[TBL] [Abstract][Full Text] [Related]
11. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research.
Earp HS; Dawson TL; Li X; Yu H
Breast Cancer Res Treat; 1995 Jul; 35(1):115-32. PubMed ID: 7612898
[TBL] [Abstract][Full Text] [Related]
12. Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.
Xu W; Yuan X; Beebe K; Xiang Z; Neckers L
Mol Cell Biol; 2007 Jan; 27(1):220-8. PubMed ID: 17030621
[TBL] [Abstract][Full Text] [Related]
13. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90.
Ren J; Bharti A; Raina D; Chen W; Ahmad R; Kufe D
Oncogene; 2006 Jan; 25(1):20-31. PubMed ID: 16158055
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the Hsp90 cochaperone cyclophilin 40 with Hsc70.
Carrello A; Allan RK; Morgan SL; Owen BA; Mok D; Ward BK; Minchin RF; Toft DO; Ratajczak T
Cell Stress Chaperones; 2004; 9(2):167-81. PubMed ID: 15497503
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
[TBL] [Abstract][Full Text] [Related]
16. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.
Stortelers C; van De Poll ML; Lenferink AE; Gadellaa MM; van Zoelen C; van Zoelen EJ
Biochemistry; 2002 Apr; 41(13):4292-301. PubMed ID: 11914075
[TBL] [Abstract][Full Text] [Related]
18. Domain-mediated dimerization of the Hsp90 cochaperones Harc and Cdc37.
Roiniotis J; Masendycz P; Ho S; Scholz GM
Biochemistry; 2005 May; 44(17):6662-9. PubMed ID: 15850399
[TBL] [Abstract][Full Text] [Related]
19. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu.
Yan YY; Zheng LS; Zhang X; Chen LK; Singh S; Wang F; Zhang JY; Liang YJ; Dai CL; Gu LQ; Zeng MS; Talele TT; Chen ZS; Fu LW
Mol Pharm; 2011 Oct; 8(5):1687-97. PubMed ID: 21812426
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
